Sugi Predict

Sugi Predict / Compounds / SCHEMBL615146

SCHEMBL615146

SCHEMBL615146

c1ccc2c(c1)oc1c(N3CCNCC3)ncnc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.72
▸ TSHR P16473 7/20 0.72
▸ HSD17B10 Q99714 7/20 0.72
▸ HTT P42858 5/20 0.72
▸ HPGD P15428 4/20 0.72
▸ MAPK1 P28482 4/20 0.72
▸ MEN1 O00255 3/20 0.72
▸ KMT2A Q03164 3/20 0.72
▸ HRH4 Q9H3N8 2/20 0.72
▸ KDM4E B2RXH2 2/20 0.72
▸ TP53 P04637 2/20 0.72
▸ HCRTR1 O43613 1/20 0.72
▸ LMNA P02545 6/20 0.70
▸ SMN1; SMN2 Q16637 6/20 0.66
▸ ALDH1A1 P00352 4/20 0.66
▸ HRH1 P35367 1/20 0.65
▸ NPSR1 Q6W5P4 2/20 0.58
▸ GAA P10253 1/20 0.58
▸ USP2 O75604 1/20 0.57
▸ HTR2C P28335 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL606545 0.84 HRH4 (1.00) MAPTTSHRHSD17B10HTTHPGD
SCHEMBL3876311 0.80 MAPT (0.73) MAPTTSHRHSD17B10HTTHPGD
SCHEMBL15304528 0.79 MAPK1 (0.75) MAPTTSHRHSD17B10HTTHPGD
SCHEMBL603432 0.79 HRH4 (1.00) MAPTTSHRHSD17B10HTTMAPK1
SCHEMBL3876308 0.79 MAPT (0.70) MAPTTSHRHSD17B10HTTHPGD
SCHEMBL13771254 0.79 MAPT (0.68) MAPTTSHRHSD17B10HTTHPGD
SCHEMBL16905930 0.74 HSD17B10 (0.59) MAPTTSHRHSD17B10HTTHPGD
SCHEMBL29554388 0.72 MAPT (0.58) MAPTTSHRHSD17B10HTTHPGD
SCHEMBL29936658 0.72 PTK2 (0.67) MAPTHSD17B10HTTHPGDMEN1
SCHEMBL1029331 0.72 PTK2 (0.67) MAPTHSD17B10HTTHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10195195-B2 Selective histamine H4 receptor antagonists for the treatment of vestibular disorders INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2019-02-05 — — US disclosed
EP-3378476-A1 H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS Sensorion (FR) 2018-09-26 — — EP disclosed
US-9688989-B2 H4 receptor inhibitors for treating tinnitus SENSORION (FR) 2017-06-27 — — US disclosed
US-20170056397-A1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-03-02 — — US disclosed
EP-3130376-A1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-02-15 — — EP disclosed
US-9526725-B2 Selective histamine H4 receptor antagonists for the treatment of vestibular disorders INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2016-12-27 — — US disclosed
EP-2382013-B1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) 2016-07-13 — — EP disclosed
US-20150176010-A1 H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS SENSORION (FR) 2015-06-25 — — US disclosed
EP-2858647-A1 H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS Sensorion (FR) 2015-04-15 — — EP disclosed
US-8999988-B2 Protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2015-04-07 — — US disclosed
US-7312226-B2 Substituted tricyclic compounds as protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2007-12-25 — — US disclosed
EP-1812113-A1 PYRIMIDINE COMPOUNDS AS HISTAMINE MODULATORS Argenta Discovery Limited (GB) 2007-08-01 — — EP disclosed
EP-1776982-A1 Pyrimidine compounds as histamine modulators Argenta Discovery Limited (GB) 2007-04-25 — — EP disclosed
EP-1678166-A2 PROTEIN KINASE INHIBITORS Arizona Board of Regents on behalf of The University of Arizona (US) 2006-07-12 — — EP disclosed
WO-2006050965-A1 PYRIMIDINE COMPOUNDS AS HISTAMINE MODULATORS ARGENTA DISCOVERY LTD (GB) 2006-05-18 — — WO disclosed
US-20050277658-A1 Protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2005-12-15 — — US disclosed
US-20050239794-A1 Protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2005-10-27 — — US disclosed
US-20050239793-A1 Protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2005-10-27 — — US disclosed
US-20050227992-A1 Protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2005-10-13 — — US disclosed
WO-2005037825-A2 PROTEIN KINASE INHIBITORS ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2005-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227992-A1 Protein kinase inhibitors CDK2, MAP3K1, MAP3K2 MAPT 4041/4885TSHR 2097/4885HSD17B10 2651/4885
US-20050277658-A1 Protein kinase inhibitors CDK2, MAP3K1, MAP3K2 MAPT 4041/4885TSHR 2097/4885HSD17B10 2651/4885
US-20050239794-A1 Protein kinase inhibitors CDK2, MAP3K1, MAP3K2 MAPT 4041/4885TSHR 2097/4885HSD17B10 2651/4885
US-20050239793-A1 Protein kinase inhibitors CDK2, MAP3K1, MAP3K2 MAPT 4041/4885TSHR 2097/4885HSD17B10 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.